Device Trial Radar · NCT07326657
Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
65
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Kerecis Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- American Burn Association; BData, Inc.
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized controlled clinical trial is to determine whether use of Kericis Intact Fish Skin Graft (IFSG) can decrease the amount of autograft tissue needed for treatment of deep partial-thickness burns in patients at least 18 years of age with a deep partial-thickness burn for whom autograft treatment is clinically indicated. This clinical trial seeks to collect the following: 1. Difference in the percentage area of the IFSG treatment site and control autograft treatment site that required autografting within 1 month of treatment 2. Proportion of subjects achieving durable wound closure of the IFSG treatment site without autograft placement within 2 months of treatment 3. Difference in cosmesis between the IFSG treatment site and autograft treatment site a year after treatment 4. Difference in the pain intensity between the IFSG treatment site and autograft treatment site Each participant will receive autograft and intact fish skin graft (IFSG) on different areas of their deep partial-thickness burn. Participants will be assessed for the need for further autograft treatment. Participants will also be assessed for wound closure, pain, and cosmesis.
Conditions
- Partial-thickness Burn Wounds
Interventions
Intact fish skin graftDevice
Treatment with IFSG
autograftProcedure
Treatment with autograft
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in percentage area of the IFSG treatment site and control autograft treatment site that required autografting by 1 month.Time frame: From initial surgical IFSG/autograft treatment post-enrollment to 28 +/- 3 days later
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Loyola University Medical Center
Maywood, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.